Literature DB >> 20413701

Elimination of soybean lipid emulsion in parenteral nutrition and supplementation with enteral fish oil improve cholestasis in infants with short bowel syndrome.

Michael D Rollins1, Eric R Scaife, W Daniel Jackson, Rebecka L Meyers, Cecilia W Mulroy, Linda S Book.   

Abstract

BACKGROUND: Parenteral nutrition-associated liver disease (PNALD) is a potentially fatal complication for children with intestinal failure. Fish oil-based lipid emulsions have shown promise for the treatment of PNALD but are not readily available. Six cases are presented in which cholestasis resolved after soybean lipid emulsion (SLE) was removed from parenteral nutrition (PN) and enteral fish oil was given.
METHODS: A retrospective review at a tertiary children's hospital (July 2003 to August 2008) identified 6 infants with intestinal failure requiring PN for >6 months who developed severe hepatic dysfunction that was managed by eliminating SLE and providing enteral fish oil.
RESULTS: Twenty-three infants with short bowel syndrome requiring prolonged PN developed cholestasis. SLE was removed in 6 of these patients, and 4 of the 6 received enteral fish oil. Standard PN included 2-3 g/kg/d SLE with total PN calories ranging from 57 to 81 kcal/kg/d at the time of SLE removal. Hyperbilirubinemia resolved after elimination of SLE within 1.8-5.4 months. Total PN calories required to maintain growth generally did not change.
CONCLUSIONS: Temporary elimination of SLE and supplementation with enteral fish oil improved cholestasis in PN-dependent infants. Further trials are needed to evaluate this management strategy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20413701     DOI: 10.1177/0884533610361477

Source DB:  PubMed          Journal:  Nutr Clin Pract        ISSN: 0884-5336            Impact factor:   3.080


  9 in total

1.  Use of parenteral fish oil to reverse cholestasis induced by parenteral nutrition in infants with intestinal failure: single-centre case series.

Authors:  Denise Reniers; Irina Rajakumar; Suzanne Ratko; Paul Atkison
Journal:  Can J Hosp Pharm       Date:  2012-01

2.  Omega-3 long chain polyunsaturated Fatty acids for treatment of parenteral nutrition-associated liver disease: a review of the literature.

Authors:  Emma M Tillman; Richard A Helms
Journal:  J Pediatr Pharmacol Ther       Date:  2011-01

Review 3.  Management and Complications of Short Bowel Syndrome: an Updated Review.

Authors:  Robert E Carroll; Enrico Benedetti; Joseph P Schowalter; Alan L Buchman
Journal:  Curr Gastroenterol Rep       Date:  2016-07

4.  The risk factors for cholestasis in patients with duodenal atresia in a single institutional cohort.

Authors:  Chiyoshi Toyama; Kazunori Masahata; Souji Ibuka; Keigo Nara; Hideki Soh; Noriaki Usui
Journal:  Pediatr Surg Int       Date:  2021-03-25       Impact factor: 1.827

5.  Lipid emulsion administered intravenously or orally attenuates triglyceride accumulation and expression of inflammatory markers in the liver of nonobese mice fed parenteral nutrition formula.

Authors:  Kyoko Ito; Lei Hao; Amanda E Wray; A Catharine Ross
Journal:  J Nutr       Date:  2013-01-16       Impact factor: 4.798

6.  Daily Enteral DHA Supplementation Alleviates Deficiency in Premature Infants.

Authors:  Michelle L Baack; Susan E Puumala; Stephen E Messier; Deborah K Pritchett; William S Harris
Journal:  Lipids       Date:  2016-02-04       Impact factor: 1.880

7.  Omega-3 Polyunsaturated Fatty Acid for Cholestasis due to Bile Duct Paucity.

Authors:  Sun Hwan Bae; Hee Sun Park; Hye Seung Han; Ik Jin Yun
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2014-06-30

Review 8.  Nutritional Feeding Strategies in Pediatric Intestinal Failure.

Authors:  Joanne Olieman; Wendy Kastelijn
Journal:  Nutrients       Date:  2020-01-08       Impact factor: 5.717

9.  The Effect of Fish Oil-Based Lipid Emulsion and Soybean Oil-Based Lipid Emulsion on Cholestasis Associated with Long-Term Parenteral Nutrition in Premature Infants.

Authors:  Leilei Wang; Jing Zhang; Jiejin Gao; Yan Qian; Ya Ling
Journal:  Gastroenterol Res Pract       Date:  2016-03-24       Impact factor: 2.260

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.